In Bahrain, GC Genome collaborated with BioLab, a prominent local diagnostics provider, to showcase ai-CANCERCH’s capabilities. The seminar drew interest from representatives of major Bahraini hospitals, who expressed enthusiasm for the technology’s potential to enhance early cancer detection. Notably, Bahrain’s government-run hospital extended an invitation for GC Genome to present at the 2025 Manama Health Congress & Expo in December, signaling strong local support for the initiative.

In Saudi Arabia, GC Genome partnered with Advanced Cell Laboratory, a CAP-accredited molecular diagnostics institution, and Genelab, the operator of the country’s largest genomic and data center, which is actively involved in national health projects. Discussions during the seminars centered on transferring advanced analytical technologies and exploring deeper collaboration to integrate ai-CANCERCH into regional healthcare systems.
Ki Chang-seok, CEO of GC Genome, highlighted the region’s potential, stating, “The Middle East’s health screening market is projected to grow from $21.8 billion in 2025 to $43.2 billion by 2031, with an annual growth rate of 11.5%.” He added, “These partnerships strengthen our regional network and lay the foundation for the widespread adoption of ai-CANCERCH across the Middle East.”
Kim Kuk Ju, HEALTH IN NEWS TEAM
press@hinews.co.kr